Share on StockTwits

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Director William C. Denby purchased 2,500 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was purchased at an average price of $5.06 per share, for a total transaction of $12,650.00. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Separately, analysts at CRT Capital reiterated a “positive” rating on shares of Adamis Pharmaceuticals Corp in a research note on Tuesday, June 24th. They now have a $15.00 price target on the stock.

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) opened at 4.83 on Thursday. Adamis Pharmaceuticals Corp has a 1-year low of $2.62 and a 1-year high of $11.90. The stock’s 50-day moving average is $3.77 and its 200-day moving average is $5.24. The company’s market cap is $50.7 million.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), formerly Cellegy Pharmaceuticals, Incoperates through its wholly owned subsidiaries Cellegy Holdings, Inc, Adamis Corporation and Biosyn, Inc Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc (Adamis Viral) and Adamis Laboratories, Inc (Adamis Labs).

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.